iratumumab
mAbexperimental
Iratumumab is a human monoclonal antibody that was investigated for treating oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2003 (NCT00059995)
Timeline
Indications
Mechanism of action
TNFRSF8 inhibitor
TNFRSF8 other
Antibody-dependent cell-mediated cytotoxicity (ADCC).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIratumumab ↗
- ChEMBLCHEMBL2108612 ↗
Also known as
- 5f11 monoclonal antibody
- iratumumab
- iratumumab
- iratumumab
- mdx-060
- mdx-060
- mdx-060 monoclonal antibody
- mdx060 monoclonal antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00298467 | Phase 2 | Feb 1, 2006 | Bristol-Myers Squibb |
| NCT00284804 | Phase 2 | Nov 1, 2005 | Bristol-Myers Squibb, Medarex |
| NCT00059995 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2003 | Cornell University, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 2 | 2 | 1 | 2005 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2003 |
| Medarex | For profit | 1 | 0 | 1 | 2005 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2003 |
4 organizations
Page 1 / 1